Articles tagged with Hiv Infections
A study by Johns Hopkins Bloomberg School of Public Health found that educational interventions can cut high-risk sexual behaviors in half and more than double the regular use of condoms. The study enrolled 3,706 men and women from public health clinics and showed significant reductions in high-risk behaviors over a one-year period.
A major HIV prevention trial involving low-income women and men living in urban areas found that behavioral interventions can reduce HIV-related sexual risk. The study, which recruited 3,700 participants, showed significant improvements in condom use and reductions in unprotected sexual acts after a one-year intervention.
The crystal structure of gp120 in action provides valuable clues for vaccine design, revealing how the virus binds to T cells while maintaining changeability. Researchers can now use this information to create targeted compounds that interfere with the interaction between gp120 and CD4 receptors.
Macrophages may proliferate in response to HIV integration, causing disease through sequential pathogenesis. Researchers identify potential DNA-interacting drugs to treat AIDS dementia.
A two-year study on the effects of marijuana in HIV patients is underway, examining its impact on the immune system, virus levels, and interactions with antiviral drugs. The trial, which began last week, will enroll 63 patients over 18 months to assess the safety of THC for HIV/AIDS treatment.
Despite initial evidence of HIV-1 infection, researchers found no conclusive cases of transient infection among exposed infants. The study suggests laboratory contamination or mislabeling as the cause of false positive test results.
Researchers identified a molecular link that enhances cell-mediated antiviral response, which is critical for suppressing HIV replication. The CD86 molecule on macrophages plays a key role in this response, and blocking its interaction with CD8+ cells reduces the immune system's ability to fight the virus.
Researchers discovered that syphilis increases HIV transmission by activating immune cells through bacterial membrane lipoproteins. This understanding could lead to treatments to slow HIV disease progression. The study found a plausible molecular explanation for why people with syphilis are more likely to transmit or contract HIV.
Researchers have created a laboratory model of AIDS by infecting tonsil tissue with HIV. The model reveals that changes in the virus's properties lead to immune system deterioration and supports the idea that environmental factors contribute to AIDS development.
Researchers found a significant association between clinic experience and survival of women with AIDS, with 71% of patients in high-experience clinics surviving 21 months after diagnosis. The study suggests that physicians who treat a certain illness more frequently may do it better, especially in HIV management.
A five-year educational campaign in Thailand has dramatically cut HIV infections and sexually transmitted diseases among young army draftees. The program, which promoted condom use, reduced the HIV rate by a factor of five and STDs by a factor of ten among those studied.
A two-month course of therapy is an effective alternative to the year-long regimen for preventing active tuberculosis in HIV-infected individuals. The study found that fewer deaths occurred among patients in the two-drug arm, with improved treatment compliance compared to the one-drug arm.
A study of 203 HIV-positive men and women found that nearly two-thirds are sexually active without disclosing their HIV status, resulting in higher rates of unprotected sex and potential transmission. Despite the risks, individuals may avoid disclosure due to fear of rejection or loss of benefits.
Researchers at NIAID have found that the virus rapidly rebounds to high levels when drugs are discontinued due to normal stimulatory factors present in the environment of a patient's lymph nodes. The new data suggest that these factors can activate HIV hidden in immune system cells, leading to their death and further viral spread.
Researchers found that heterozygous children with the delta 32 mutation experienced slower disease progression and delayed onset of severe immunodeficiency. This discovery provides important arguments for the beneficial effect of delta 32 heterozygosity on HIV disease progression in children.
Researchers at the University of Pennsylvania School of Medicine are conducting a new clinical trial combining a proven antiretroviral drug therapy with an experimental DNA vaccine to eradicate HIV. The therapy has shown promise in lowering virus levels and restoring immune system function, paving the way for a potential cure.
A study published in the Journal of the American Medical Association found that certain symptoms like fever, joint pain, and night sweats can identify people with recent HIV infection before a positive blood test. The researchers screened over 3,800 patients and found that those with these symptoms were more likely to have the virus.
A recent study found that risk factors for HIV infection among married women in India include having a sex partner with a sexually transmitted disease. The researchers discovered a significant correlation between HIV transmission and the cultural norm of not discussing sexual behavior, emphasizing the need for accessible STD prevention...
Recent studies have identified key risk factors and clinical symptoms associated with acute HIV infection in India, particularly among commercial sex workers. The findings highlight the importance of p24 antigen screening to detect infections early, reducing the accuracy of previously described signs and symptoms., Condom distribution ...
Researchers have developed a system to mimic the thymus in laboratory settings, enabling the study of HIV's effect on T-cell development. The model has shown that even immature T cells are susceptible to HIV infection, highlighting the need for treatment targeting young individuals.
Researchers at MGH have discovered a new immune response that may help control HIV levels in the body. In a study of chronically infected individuals and long-term nonprogressors, the team found that those with strong HIV-specific helper T-cell responses had lower viral loads, suggesting a potential therapeutic target.
Researchers have developed a novel gene-therapy strategy to target HIV-infected cells using the virus's molecular tools against it. The technique, which employs therapeutic genes only in infected cells, has broad applicability and could potentially cure HIV infection.
Despite prolonged treatment with combination antiretroviral therapy, HIV persists and can replicate in patients with no detectable virus in their blood. Researchers found that resting CD4+ T cells serve as a stable 'reservoir' of virus, allowing it to continue replicating even when undetectable.
A study found that HIV remains in a dormant state within CD4+ lymphocytes even after treatment with triple-drug cocktail therapy. This persistence suggests individuals must continue multiple-drug therapy to prevent reactivation of the infection.
Researchers found that cytotoxic T-lymphocytes (CTLs) can recognize and target different HIV strains, suggesting a potential universal vaccine. CTLs play a key role in the immune response against HIV, with high levels seen in long-term nonprogressors and individuals who remain uninfected despite multiple exposures.
HIV scientists discovered a biochemical cascade initiated by virus envelope proteins that activate cells and increase their vulnerability to infection. The study found macrophage-tropic viruses use CD4 and CCR5 for cell entry, while T-cell tropic strains do not trigger signalling.
Researchers at Oregon Health Sciences University have found that HIV infection of endothelial cells leads to the development of cancerous B-cells in AIDS patients. The virus disrupts normal signaling mechanisms, causing an increased number of adhesion molecules to form and support the growth of malignant cells.
Researchers have discovered a small peptide called ALX40-4C that blocks the CXCR4 coreceptor used by HIV-1 to infect T cells. This breakthrough suggests a potential new generation of combination therapies that could delay or prevent HIV infection and AIDS progression.
Researchers found that HIV gene vpr blocks cytokine production in infected cells, preventing immune activation. Vpr also prevents apoptosis in infected cells but induces apoptosis in neighboring immune cells, making it harder for the body to defend against the infection. The antisteroid compound RU-486 reversed many of these effects.
Researchers develop novel approach to block HIV virus from invading white blood cells, potentially treating AIDS patients with genetic modification and reinfusion of immune-boosting lymphocytes. This strategy may provide a new paradigm for HIV treatment, protecting cells from infection rather than inhibiting replication.
The study aims to measure how effectively combination drug therapy works during the early stages of HIV infection, with a focus on reducing damage caused by the virus. Researchers hope to determine the optimal duration of treatment for maximum benefit and assess the impact of early treatment on immune system chemicals.
A recent study found that a genetic mutation in the CCR5 gene does not fully explain why some people infected with HIV remain healthy for years. Instead, researchers attribute their good health to various factors, including immune system components and viral factors. The investigation involved 33 patients from different cohorts and rev...
Researchers have discovered a naturally occurring chemokine antagonist, vMIP-II, which can block both CCR5 and CXCR4 receptors used by HIV to infect human cells. This breakthrough may lead to novel approaches for HIV therapy, including prevention of initial infection and slowing disease progression.
A team of researchers has developed a virus that controls HIV infection by targeting infected T cells. The modified virus, VSV, tricks infected cells into fusing with it instead of normal cells, allowing it to destroy the virus. This approach could lead to new treatments for HIV and other diseases.
A new UNC-CH study found that an antiretroviral drug reduced HIV transmission in men, suggesting a potential decrease in the probability of transmission. The study showed significant drops in virus levels and undetectable HIV in eight out of 11 subjects.
Researchers found that treating co-infections with sexually transmitted diseases (STDs) significantly reduces the amount of virus shed in semen, making transmission less likely. The study suggests widespread STD screening and therapy could be a crucial step in combating HIV/AIDS globally.
A new study reveals that tissue macrophages play a critical role in triggering the production of HIV in patients with AIDS, leading to increased virus levels despite declining CD4 T cell counts. This finding highlights the importance of controlling opportunistic infections to slow the cycle of virus production.
Researchers at Johns Hopkins Children's Center have found that certain metabolites of an antipsychotic drug inhibit HIV replication in human cell cultures, but at high concentrations. The findings suggest possible anti-viral activity against other viruses.
Researchers at the University of Rochester and UCLA have discovered a novel way to target HIV by genetically engineering a mutant tRNA primer that disrupts the virus's replication process. The approach, which has been patented, opens up new avenues for gene therapy in AIDS treatment.
A study found thalidomide effective in healing 55% of HIV patients' mouth ulcers, while also improving comfort during eating. However, the treatment's potential for irreversible nerve damage and other side effects require careful monitoring.
Researchers have discovered that HIV can invade cells within any female reproductive tract organ, increasing the risk of infection. The study's findings suggest that vaccine development and disease prevention should aim to confer protection throughout the entire tract.
Scientists measured viral load in 106 HIV-infected babies from birth to 5 years of age, finding that higher viral loads predict disease severity. Early HIV blood levels may also predict outcome of progression to AIDS in children, highlighting the need for early antiretroviral therapy.
Scientists at Johns Hopkins Medicine report a test that counts AIDS viruses in blood can identify infected infants and extend their lives by starting treatment early. The test shows within a month after birth whether a baby born to an HIV-positive mother is also infected, allowing for prompt intervention.
Researchers identified three key factors that significantly boost the spread of HIV: having other STDs, multiple sexual relationships, and sex with people newly infected. Increasing STD detection and treatment, and focusing on early HIV infections can help curb the epidemic.
A potent chemokine, AOP-RANTES, has been shown to inhibit HIV-1 entry into macrophages and lymphocytes at the nanomolar level. Researchers believe this could lead to a new treatment approach for HIV/AIDS by targeting host cells to prevent viral entry.
A recent study by the National Institute of Allergy and Infectious Diseases (NIAID) found that women using N-9 film with condoms had an overall rate of HIV transmission of 6.7%, significantly lower than previously estimated rates in this population.
A study has found that human chorionic gonadotropin (hCG) reduces HIV viral protein production and protects against skin lesions in transgenic mice. The hormone may also explain the low rate of mother-to-infant HIV transmission, and has potential for treating wasting syndrome in children and adults.
Researchers at the University of Pennsylvania School of Medicine have discovered a new antibody that targets the CXCR4 receptor, a molecule involved in HIV infection. The antibody, termed 12G5, has been shown to block some types of HIV from infecting cells and has enormous value for HIV investigators.
The Pediatric ACTG Protocol 185 clinical trial was stopped early due to an unexpectedly low rate of infant HIV infection, making it impossible to compare treatment outcomes. The study confirmed the effectiveness of AZT in reducing mother-to-child HIV transmission, extending its benefits to women with more advanced disease and previous ...
Researchers found that self-administered IL-2 injections can produce significant increases in CD4+ T cells in HIV-infected patients. Those with higher initial CD4+ T cell counts had the best responses, with almost half sustaining increases of at least 200 cells/mm³ after one year.
Preliminary results from ACTG 315 show that an antiretroviral drug cocktail can partially restore immune function in people with moderately advanced HIV disease. The study found increases in CD4+ T cell counts, decreased plasma levels of HIV, and improved immune response.
Researchers have identified key chemokine receptors that enable HIV to infect immune system cells, including CCR5 and CCR-3. Understanding these interactions could lead to the development of new treatments and prevention strategies for HIV/AIDS.
Researchers found that certain patterns of immune responses to HIV during primary infection are highly predictive of an individual's subsequent rate of disease progression. The study suggests that the immunologic factors at work during this early period, as much or more than virologic factors, determine the outcome of HIV disease.
Recent advances in HIV research reveal the critical role of host factors in determining disease progression and replication rates. Key discoveries include the regulation of HIV replication by immune response molecules and the activation of the immune system by the virus.
A recent study published in The Lancet found that a specific HIV vaccine, MNrgp120, did not stop the virus from reproducing or slow immune system destruction. Researchers evaluated 568 volunteers infected with HIV and found no significant differences in CD4 counts between those who received the vaccine and those who received a placebo.
A recent analysis of ACTG 076 data found that the risk of perinatal transmission of HIV can occur even when a woman has little or no detectable virus in her blood. Offering AZT therapy to all pregnant HIV-infected women is crucial, regardless of their stage of disease.
Emory University researchers identified a subpopulation of HIV-infected infants with a thymic-defect profile, characterized by low CD4+ and CD8+ T cell counts. These high-risk infants were found to develop AIDS symptoms sooner and have increased mortality rates compared to those without the profile.
The study results provided conclusive evidence that antiretroviral therapy can reduce the risk of death in people with intermediate-stage HIV disease. Combination therapies showed promise in slowing disease progression and reducing mortality rates, particularly in patients without prior antiretroviral treatment.
A recent study found that patients with vancomycin-resistant enterococcal infections acquired them in hospitals, resulting in high mortality rates and increased treatment costs. The study highlights the need for proper antibiotic utilization and collaboration among healthcare professionals to prevent antibiotic resistance.
A study conducted by the University of Washington found that HIV transmission can occur even among individuals with few sexual partners, and that oral sex is a common route of transmission among gay men. Despite warnings from health experts, unprotected oral sex may not be as safe as previously thought.